Build, et al - Seems to me that GNBT may be experiencing a level of authority issue - executives that have the power to make a deal up to a certain level on their own authority but need board approval for expenditures greater than that. The $100k being done on an individuals authority (the lady mentioned in the December PR requesting the time extension to Dec 31?) explaining why it was received quickly, but for the $5 m payment, board authority being required. If one of the parties of the partnership is the Chinese CDC, then the CCP is going to be involved. Maybe it's the current strained relationship (which, btw, I wholeheartedly endorse considering how China handled "containment" of the virus) or maybe it's just bureaucratic red tape - communist or republic, gov't is gov't and history shows few things get done quickly.
Not saying the CCP won't approve it, but I am saying bringing that level of politics into the process is likely to delay the approval. Whether that is a day, a week or a month, we'll all find out together some day when a PR is released. Let's hope it's sooner rather than later.
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links